<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348658</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-536TCH/CPH-004</org_study_id>
    <secondary_id>U1111-1165-5595</secondary_id>
    <secondary_id>JapicCTI-152777</secondary_id>
    <nct_id>NCT02348658</nct_id>
  </id_info>
  <brief_title>A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Food-Effect of Single Oral Dose of TAK-536TCH Final Formulation Tablet in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, open-label, crossover study to evaluate the food-effect of
      single oral dose of TAK-536TCH final formulation tablet in healthy adult male participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the food effect on the pharmacokinetics and safety
      of a single oral dose of TAK-536TCH under fasted and fed conditions in the morning in healthy
      adult male participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ)</measure>
    <time_frame>Day 1: predose and at multiple time points (up to 48 hours) postdose in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Plasma Concentration for Amlodipine Besilate (AML)</measure>
    <time_frame>Day 1: predose and at multiple time points (up to 120 hours) postdose in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</measure>
    <time_frame>Day 1: predose and at multiple time points (up to 48 hours) postdose in each period</time_frame>
    <description>AUC(0-48) is a measure of the area under the plasma concentration time-curve from time 0 to 48 hours postdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose in Each Period for AML</measure>
    <time_frame>Day 1: predose and at multiple time points (up to 120 hours) postdose in each period</time_frame>
    <description>AUC(0-120) is a measure of the area under the plasma concentration time-curve from time 0 to 120 hours postdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</measure>
    <time_frame>Day 1: predose and at multiple time points (up to 48 hours) postdose in each period</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for AML</measure>
    <time_frame>Day 1: predose and at multiple time points (up to 120 hours) postdose in each period</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</measure>
    <time_frame>Day 1: predose and at multiple time points (up to 48 hours) postdose in each period</time_frame>
    <description>AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for AML</measure>
    <time_frame>Day 1: predose and at multiple time points (up to 120 hours) postdose in each period</time_frame>
    <description>AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Excretion Ratio of TAK-536, Its Metabolites (M-I and M-II) and HCTZ</measure>
    <time_frame>Day 1: predose and at multiple time-points (up to 48 hours) postdose in each period</time_frame>
    <description>Urinary excretion ratio (percent [%] of dose) of TAK-536, its metabolite M-I, M-II and HCTZ in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected in each pooling period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Excretion Ratio of AML</measure>
    <time_frame>Day 1: predose and at multiple time-points (up to 120 hours) postdose in each period</time_frame>
    <description>Urinary excretion ratio (% of dose) of AML in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected in each pooling period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs Related to Vital Signs</measure>
    <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs Related to Body Weight</measure>
    <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values</measure>
    <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Significant Findings in Electrocardiograms After Study Drug Administration</measure>
    <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
    <description>Participants whose results of electrocardiograms were judged as abnormal and clinically significant by investigator after study drug administration were counted in this measurement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Fasted dosing followed by fed dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dosing in the fasted state followed by fed dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed dosing followed by fasted dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dosing in the fed state followed by fasted dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-536TCH</intervention_name>
    <description>TAK-536TCH tablets</description>
    <arm_group_label>Fasted dosing followed by fed dosing</arm_group_label>
    <arm_group_label>Fed dosing followed by fasted dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. In the opinion of the investigator and subinvestigator, the participant is capable
             of understanding and complying with protocol requirements.

             2. The participant signs and dates a written, informed consent form prior to the
             initiation of any study procedures.

             3. The participant is a healthy Japanese adult male. 4. The participant is aged 20 to
             35 years, inclusive at the time of informed consent.

             5. The participant weighs at least 50.0 kg and has a body mass index (BMI) from 18.5
             to 25.0 kilograms per square meter (kg/m^2), inclusive at Screening.

        Exclusion Criteria:

          1. Participant has systolic blood pressure less-than (&lt;) 90 millimeters of mercury (mmHg)
             at Screening.

          2. Participant has suspected hypotension and associated physical findings, such as
             dizziness postural, facial pallor, or cold sweats based on evaluation/physical
             examination at Screening, on Day -1 of Period 1, or up to administration on the Period
             1.

          3. The participant has received any study drug within 16 weeks (that is [i.e.], 112 days)
             prior to study drug administration of Period 1.

          4. The participant has received TAK-491*, TAK-536, amlodipine, or hydrochlorothiazide in
             a previous clinical study or as a therapeutic agent.

          5. The participant has uncontrolled, clinically significant neurologic, cardiovascular,
             pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, or endocrine
             disease, or other abnormality (other than the disease studied), which could impact the
             ability of the participant to participate or potentially confound the study results.

          6. Participant has a known hypersensitivity to drugs.

          7. Participant has a positive urine drug result for drugs of abuse at Screening.

          8. Participant has a history of drug abuse (defined as any illicit drug use) or a history
             of alcohol abuse within 2 years prior to the Screening visit or was unwilling to agree
             to abstain from alcohol and drugs throughout the study.

          9. Participant required any prohibited concomitant drugs, vitamins, or food products
             listed in the prohibited concomitant drugs and foods table.

         10. Participant has current or recent (within 6 months) gastrointestinal disease that
             would be expected to influence the absorption of drugs (i.e., a history of
             malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent
             [more than once per week] occurrence of heartburn, or any surgical intervention [e.g.,
             cholecystectomy]).

         11. Participant has a history of cancer.

         12. Participant has a positive test result for hepatitis B surface antigen (HBsAg),
             hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen,
             or serological reactions for syphilis at Screening.

         13. Participant has poor peripheral venous access.

         14. Participant has undergone whole blood collection of at least 200 mL within 4 weeks (28
             days) or at least 400 mL within 12 weeks (84 days) prior to study drug administration
             in Period 1.

         15. Participant has undergone whole blood collection of at least 800 mL in total within 52
             weeks (364 days) prior to study drug administration in Period 1.

         16. Participant has undergone blood component collection within 2 weeks (14 days) prior to
             study drug administration in Period 1.

         17. Participant has a hemoglobin value of less than 12.5 g/dL in laboratory testing at
             Screening or prior to study drug administration in Period 1.

         18. Participant has a clinically significant ECG abnormality at Screening or prior to
             study drug administration in Period 1.

         19. Participant has abnormal laboratory values at Screening or prior to study drug
             administration of Period 1 that suggest a clinically significant underlying disease or
             participant with the following lab abnormalities: alanine aminotransferase (ALT) or
             aspartate aminotransferase (AST) is &gt;1.5-fold the upper limits of normal range.

         20. Participant who, in the opinion of the investigator, is unlikely to comply with the
             protocol or is unsuitable for any other reason.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <results_first_submitted>March 24, 2016</results_first_submitted>
  <results_first_submitted_qc>March 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2016</results_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacological therapy</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Japan from 29 January 2015 to 11 March 2015.</recruitment_details>
      <pre_assignment_details>Healthy adult male participants were enrolled in 1 of 2 treatment sequences in either of the Periods 1 or 2: Sequence A: TAK-536TCH (combination drug of TAK-536 [azilsartan], amlodipine besilate [AML], hydrochlorothiazide [HTZ]) Fasted in Period 1+ TAK-536TCH Fed in period 2; Sequence B: TAK-536TCH Fed in Period 1+ TAK-536TCH Fasted in Period 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-536TCH Fasted + TAK-536TCH Fed</title>
          <description>TAK-536TCH (20 milligram [mg]/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in Period 1, followed by 22 days washout period, followed by TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in Period 2.</description>
        </group>
        <group group_id="P2">
          <title>TAK-536TCH Fed + TAK-536TCH Fasted</title>
          <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in Period 1, followed by 22 days washout period, followed by TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (22 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pharmacokinetic (PK) analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants who received either 1 of the two treatment sequences: Sequence 1: TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in Period 1, followed by 22 days washout period, followed by TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in Period 2 or Sequence 2: TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in Period 1, followed by 22 days washout period, followed by TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in Period 2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.2" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.3" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.18" spread="5.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.85" spread="1.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Drinks a few Days per Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had Never Drunk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caffeine Consumer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine Non-Consumer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ)</title>
        <time_frame>Day 1: predose and at multiple time points (up to 48 hours) postdose in each period</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ)</title>
          <population>Pharmacokinetic (PK) analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-536</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1912.0" spread="253.39"/>
                    <measurement group_id="O2" value="1783.7" spread="318.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448.3" spread="143.36"/>
                    <measurement group_id="O2" value="455.3" spread="131.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="453.5" spread="109.75"/>
                    <measurement group_id="O2" value="451.9" spread="101.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCTZ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.4" spread="30.481"/>
                    <measurement group_id="O2" value="101.6" spread="14.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Plasma Concentration for Amlodipine Besilate (AML)</title>
        <time_frame>Day 1: predose and at multiple time points (up to 120 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Plasma Concentration for Amlodipine Besilate (AML)</title>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.752" spread="0.5124"/>
                    <measurement group_id="O2" value="3.668" spread="0.6468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</title>
        <description>AUC(0-48) is a measure of the area under the plasma concentration time-curve from time 0 to 48 hours postdose.</description>
        <time_frame>Day 1: predose and at multiple time points (up to 48 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</title>
          <description>AUC(0-48) is a measure of the area under the plasma concentration time-curve from time 0 to 48 hours postdose.</description>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-536</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14599.8" spread="2254.31"/>
                    <measurement group_id="O2" value="13279.4" spread="2889.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3215.8" spread="698.75"/>
                    <measurement group_id="O2" value="2693.8" spread="706.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9093.3" spread="1711.69"/>
                    <measurement group_id="O2" value="8990.8" spread="2310.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCTZ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670.8" spread="75.912"/>
                    <measurement group_id="O2" value="595.2" spread="68.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose in Each Period for AML</title>
        <description>AUC(0-120) is a measure of the area under the plasma concentration time-curve from time 0 to 120 hours postdose.</description>
        <time_frame>Day 1: predose and at multiple time points (up to 120 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose in Each Period for AML</title>
          <description>AUC(0-120) is a measure of the area under the plasma concentration time-curve from time 0 to 120 hours postdose.</description>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.370" spread="27.7395"/>
                    <measurement group_id="O2" value="125.749" spread="26.9893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Day 1: predose and at multiple time points (up to 48 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-536</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14599.8" spread="2254.31"/>
                    <measurement group_id="O2" value="13279.4" spread="2889.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3215.8" spread="698.75"/>
                    <measurement group_id="O2" value="2693.8" spread="706.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9093.3" spread="1711.69"/>
                    <measurement group_id="O2" value="8990.8" spread="2310.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCTZ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="641.3" spread="87.752"/>
                    <measurement group_id="O2" value="556.4" spread="70.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for AML</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Day 1: predose and at multiple time points (up to 120 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for AML</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.370" spread="27.7395"/>
                    <measurement group_id="O2" value="125.749" spread="26.9893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</title>
        <description>AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
        <time_frame>Day 1: predose and at multiple time points (up to 48 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ</title>
          <description>AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-536</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15077.4" spread="2433.01"/>
                    <measurement group_id="O2" value="13700.9" spread="3154.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3271.3" spread="708.48"/>
                    <measurement group_id="O2" value="2755.1" spread="727.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10496.0" spread="2221.49"/>
                    <measurement group_id="O2" value="10193.0" spread="2804.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCTZ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="673.5" spread="87.075"/>
                    <measurement group_id="O2" value="595.9" spread="69.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for AML</title>
        <description>AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
        <time_frame>Day 1: predose and at multiple time points (up to 120 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for AML</title>
          <description>AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.</description>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.941" spread="37.5121"/>
                    <measurement group_id="O2" value="140.484" spread="34.4402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Excretion Ratio of TAK-536, Its Metabolites (M-I and M-II) and HCTZ</title>
        <description>Urinary excretion ratio (percent [%] of dose) of TAK-536, its metabolite M-I, M-II and HCTZ in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected in each pooling period.</description>
        <time_frame>Day 1: predose and at multiple time-points (up to 48 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion Ratio of TAK-536, Its Metabolites (M-I and M-II) and HCTZ</title>
          <description>Urinary excretion ratio (percent [%] of dose) of TAK-536, its metabolite M-I, M-II and HCTZ in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected in each pooling period.</description>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>percentage of dose</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-536</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.682"/>
                    <measurement group_id="O2" value="13.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076"/>
                    <measurement group_id="O2" value="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.275"/>
                    <measurement group_id="O2" value="19.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCTZ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.742"/>
                    <measurement group_id="O2" value="74.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Excretion Ratio of AML</title>
        <description>Urinary excretion ratio (% of dose) of AML in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected in each pooling period.</description>
        <time_frame>Day 1: predose and at multiple time-points (up to 120 hours) postdose in each period</time_frame>
        <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion Ratio of AML</title>
          <description>Urinary excretion ratio (% of dose) of AML in urine were calculated for each participant. Ratio was calculated from the urine concentrations of each analyte and the volume of urine collected in each pooling period.</description>
          <population>PK analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.</population>
          <units>percentage of dose</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.843"/>
                    <measurement group_id="O2" value="7.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</title>
        <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
        <population>Safety analysis set included all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)</title>
          <population>Safety analysis set included all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs Related to Vital Signs</title>
        <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
        <population>Safety analysis set included all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Vital Signs</title>
          <population>Safety analysis set included all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs Related to Body Weight</title>
        <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
        <population>Safety analysis set included all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Body Weight</title>
          <population>Safety analysis set included all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values</title>
        <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
        <population>Safety analysis set included all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values</title>
          <population>Safety analysis set included all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Significant Findings in Electrocardiograms After Study Drug Administration</title>
        <description>Participants whose results of electrocardiograms were judged as abnormal and clinically significant by investigator after study drug administration were counted in this measurement.</description>
        <time_frame>Baseline up to 14 days after last dose of study drug (14 days after Day 1 of Period 2 )</time_frame>
        <population>Safety analysis set included all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-536TCH Fasted</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-536TCH Fed</title>
            <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Significant Findings in Electrocardiograms After Study Drug Administration</title>
          <description>Participants whose results of electrocardiograms were judged as abnormal and clinically significant by investigator after study drug administration were counted in this measurement.</description>
          <population>Safety analysis set included all participants who received the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 14 days for a serious adverse event after the last dose of study drug (14 days after Day 1 of Period 2).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-536TCH Fasted</title>
          <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fasted condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
        </group>
        <group group_id="E2">
          <title>TAK-536TCH Fed</title>
          <description>TAK-536TCH (20 mg/5 mg/12.5 mg), tablet, in fed condition, orally, once on Day 1 in either Period 1 or Period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (v18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

